Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Recruiting 5

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3Observational 2

Sponsor

Conditions

Myasthenia Gravis 5Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1

Interventions

rozanolixizumab 8zilucoplan 7ravulizumab 6fludarabine 5efgartigimod alfa 5Cyclophosphamide 5telitacicept 3Prednisone 3inebilizumab 2Rituximab 2Pyridostigmine Bromide 2tofacitinib 1thymoglobulin 1talquetamab 1remibrutinib 1prednylidene 1iptacopan 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Walk Test 1Therapeutics 1Tacrolimus 1Steroids 1Robotic Surgical Procedures 1Psychodrama 1Prednisolone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Myasthenia Gravis × efgartigimod alfa × 1 year × Clear all
NCT07217587 2026-06-05

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting
115 enrolled

Myasthenia Gravis

NCT06298565 2026-02-17

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

argenx

Recruiting
680 enrolled

Myasthenia Gravis

NCT06299748 2026-02-17

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

argenx

Recruiting
279 enrolled

Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07072988 2025-09-24

OPTIMAGE

Centre Hospitalier Universitaire de Nice

Phase 4 Recruiting
50 enrolled

Myasthenia Gravis

NCT06765161 2025-07-29

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Clinique Neuro-Outaouais

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡